Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
Exelixis Inc reports results for the quarter ended March 31 - Earnings Summary
Exelixis Inc EXEL.OQ reported quarterly adjusted earnings of 82 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 55 cents. The mean expectation of nineteen analysts for the quarter was for earnings of 70 cents per share. Wall Street expected results to range from 62 cents to 89 cents per share.
Revenue rose 7.5% to $610.81 million from a year ago; analysts expected $635.95 million.
Exelixis Inc's reported EPS for the quarter was 79 cents.
The company reported quarterly net income of $212.05 million.
Exelixis Inc shares had risen by 2.9% this quarter and gained 27.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 11.7% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 11 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Exelixis Inc is $54.00, about 3.7% below its last closing price of $56.00
This summary was machine generated from LSEG data August 5 at 09:56 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Mar. 31 2026 | 0.70 | 0.82 | Beat |
Dec. 31 2025 | 0.81 | 0.79 | Missed |
Dec. 31 2025 | 0.62 | 0.69 | Beat |
Jun. 30 2025 | 0.56 | 0.69 | Beat |